I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Cost-effectiveness analysis of using atorvastatin, simvasta..:
T. O. Bessonova
;
P. A. Mukhortova
;
R. A. Teryan
...
https://www.pharmacoeconomics.ru/jour/article/view/794/458. , 2023
Link:
https://www.pharmacoeconomics.ru/jour/article/view/794
RT Journal T1
Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program ; Оценка клинико-экономической целесообразности применения лекарственных препаратов эзетимиб, алирокумаб, эволокумаб и инклис...
UL https://suche.suub.uni-bremen.de/peid=base-ftjpharmaeconom:oai:oai.farmaec.elpub.ru:article_794&Exemplar=1&LAN=DE A1 T. O. Bessonova A1 P. A. Mukhortova A1 R. A. Teryan A1 A. D. Bagdasarov A1 N. Z. Musina A1 Т. О. Бессонова A1 П. А. Мухортова A1 Р. А. Терян A1 А. Д. Багдасаров A1 Н. З. Мусина PB IRBIS LLC YR 2023 K1 инклисиран K1 pharmaceutical benefit K1 high cardiovascular risk K1 ezetimibe K1 alirocumab K1 evolocumab K1 inclisiran K1 льготное лекарственное обеспечение K1 высокий сердечно-сосудистый риск K1 эзетимиб K1 алирокумаб K1 эволокумаб JF https://www.pharmacoeconomics.ru/jour/article/view/794/458 LK http://dx.doi.org/https://www.pharmacoeconomics.ru/jour/article/view/794 DO https://www.pharmacoeconomics.ru/jour/article/view/794 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)